XFOR Stock Price, X4 Pharmaceuticals Inc Quote, Chart

Market Summary

USD0.93-0.03

Delayed

-3.13%

XFOR Stock Price

View Fullscreen

XFOR RSI Chart

XFOR Valuation

Market Cap

156.2M

Price/Earnings (Trailing)

-1.21

Price/Sales (Trailing)

61.02

EV/EBITDA

-0.78

Price/Free Cashflow

-1.11

XFOR Price/Sales (Trailing)

XFOR Profitability

EBT Margin

-4294.00%

Return on Equity

-12.4K%

Return on Assets

-114.91%

Free Cashflow Yield

-90.17%

XFOR Fundamentals

XFOR Revenue

Revenue (TTM)

3.0M

XFOR Earnings

Earnings (TTM)

-128.9M

Earnings Growth (Yr)

-115.51%

Earnings Growth (Qtr)

-170.6%

Breaking Down XFOR Revenue

Last 7 days

-11.4%

Last 30 days

-22.5%

Last 90 days

1.1%

Trailing 12 Months

-52.1%

How does XFOR drawdown profile look like?

XFOR Financial Health

Current Ratio

3.71

XFOR Investor Care

Shares Dilution (1Y)

37.42%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	5.7M	5.2M	3.2M	3.0M
2018	3.6M	3.3M	3.7M	3.2M
2017	2.8M	3.1M	3.5M	3.9M
2016	0	0	0	2.4M
2015	0	0	0	2.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of X4 Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	mostafa adam s.	sold	-46,347	0.8828	-52,500	chief financial officer
Mar 11, 2024	taveras arthur	sold	-12,552	0.8818	-14,235	chief scientific officer
Mar 11, 2024	ragan paula	sold	-43,855	0.8828	-49,678	president and ceo
Mar 11, 2024	dibiase mary	sold	-13,590	0.882	-15,409	chief operating officer
Feb 12, 2024	dibiase mary	sold	-3,708	1.007	-3,683	chief operating officer
Feb 12, 2024	ragan paula	sold	-21,892	1.0091	-21,695	president and ceo
Feb 12, 2024	mostafa adam s.	sold	-27,973	1.0091	-27,721	chief financial officer
Feb 12, 2024	taveras arthur	sold	-792	1.0072	-787	chief scientific officer
Nov 03, 2023	ragan paula	sold	-35,915	0.9	-39,906	president and ceo
Nov 01, 2023	mostafa adam s.	sold	-168,371	0.73	-230,645	chief financial officer

Which funds bought or sold XFOR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-40.09	-739	107,657	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-37.86	512	17,504	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	1,354	1,410,880	1,471,910	-%
May 15, 2024	STATE STREET CORP	added	3.94	1,472,040	3,507,740	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	reduced	-78.14	-87,862	49,939	-%
May 15, 2024	Point72 Asset Management, L.P.	unchanged	-	358,475	903,500	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-55.86	-388,615	1,060,370	-%
May 15, 2024	Voya Investment Management LLC	reduced	-17.58	15,126	56,431	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	reduced	-23.38	393,965	1,856,370	0.13%
May 15, 2024	Royal Bank of Canada	reduced	-92.72	-29,000	4,000	-%

Are Funds Buying or Selling XFOR?

Are funds buying XFOR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XFOR

No. of Funds

Unveiling X4 Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	acorn bioventures, l.p.	4.8%	8,205,816	SC 13G
Feb 14, 2024	lincoln park capital fund, llc	947%	1,600,136	SC 13G/A
Feb 14, 2024	orbimed advisors llc	6.7%	11,494,437	SC 13G/A
Feb 13, 2024	bain capital life sciences fund, l.p.	9.99%	16,915,784	SC 13G/A
Feb 07, 2024	blackrock inc.	4.9%	8,160,747	SC 13G/A
Jan 31, 2024	blackrock inc.	5.0%	8,417,524	SC 13G
Jan 16, 2024	millennium management llc	1.0%	1,664,317	SC 13G/A
Jan 08, 2024	empery asset management, lp	2.65%	4,549,605	SC 13G/A
Jun 16, 2023	millennium management llc	5.2%	8,268,816	SC 13G
May 26, 2023	growth equity opportunities 18 vge, llc	9.99%	15,742,792	SC 13D/A

Recent SEC filings of X4 Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 05, 2024	8-K	Current Report
Apr 01, 2024	8-K	Current Report

Peers (Alternatives to X4 Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

X4 Pharmaceuticals Inc News

Latest updates

X4 Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2015Q4
Revenue	-	-	-	-	3.00	0.00	2.00	1.00	0.00	1.00	2.00	1.00	1.00	-	-
Operating Expenses	4.0%	18.00	17.00	15.00	14.00	13.00	9.00	6.00	-	-	-	-	-	-	-
S&GA Expenses	-4.3%	5.00	6.00	5.00	5.00	3.00	2.00	2.00	1.00	-	-	-	-	-	-
R&D Expenses	8.1%	12.00	11.00	9.00	9.00	5.00	6.00	5.00	-	-	-	-	-	-	-
Interest Expenses	3.3%	1.00	1.00	1.00	1.00	0.00	0.00	0.00	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-5.5%	-18.40	-17.45	-15.14	-10.99	-	-	-	-	-	-	-	-	-	-
Net Income	-5.5%	-18.40	-17.45	-15.14	-11.14	-9.36	-8.60	-6.03	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-23.8%	112	147	173	173	124	156	113	81.00	100	117	121	142	161	123	133	143	154	161	110	134	63.00
Current Assets	-28.5%	87.00	122	148	148	98.00	129	86.00	53.00	71.00	88.00	81.00	101	120	83.00	94.00	110	122	129	79.00	97.00	26.00
Cash Equivalents	-38.2%	61.00	99.00	132	136	93.00	122	81.00	49.00	68.00	82.00	78.00	96.00	117	81.00	89.00	104	115	128	76.00	90.00	22.00
Net PPE	-0.4%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	27.00	27.00	27.00	27.00	27.00	27.00	27.00	27.00	27.00	27.00	27.00
Liabilities	15.6%	111	96.00	106	106	73.00	82.00	52.00	51.00	50.00	53.00	52.00	52.00	54.00	50.00	43.00	38.00	35.00	31.00	30.00	37.00	33.00
Current Liabilities	3.0%	24.00	23.00	25.00	22.00	19.00	22.00	29.00	22.00	15.00	14.00	13.00	13.00	15.00	12.00	13.00	11.00	8.00	9.00	8.00	13.00	16.00
LT Debt, Current	-	-	-	-	1.00	1.00	1.00	15.00	9.00	3.00	1.00	1.00	-	-	-	-	-	-	-	-	4.00	5.00
Shareholder's Equity	-98.0%	1.00	51.00	68.00	68.00	52.00	74.00	62.00	30.00	50.00	64.00	69.00	87.00	105	73.00	90.00	105	119	129	79.00	96.00	29.00
Retained Earnings	-10.8%	-529	-477	-458	-456	-400	-376	-347	-326	-304	-282	-252	-232	-212	-194	-175	-158	-143	-132	-121	-103	-90.11
Additional Paid-In Capital	0.3%	531	529	526	524	452	451	410	356	355	347	321	320	318	267	266	263	262	261	200	200	120
Shares Outstanding	0.3%	168	167	165	164	122	122	83.00	35.00	34.00	26.00	27.00	24.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	318	-	-	-	30.00	-	-	-	158	-	-	-	145	-	-	-	184	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-454.8%	-33,600	9,471	-68,800	-47,900	-26,500	-19,093	-19,306	-18,474	-20,229	-19,053	-14,211	-19,197	-18,444	-17,504	-14,328	-11,459	-15,527	-9,241	-12,772	-14,292	-11,750
Share Based Compensation	-31.5%	1,739	2,539	2,361	2,142	1,645	1,107	1,111	1,522	1,459	1,609	1,516	1,797	1,258	1,398	2,244	1,173	613	664	691	433	262
Cashflow From Investing	-10.1%	-5,322	-4,833	-5,157	-4,884	-9.00	-34.00	-9.00	-38.00	-22.00	-13.00	-20.00	-86.00	-496	-302	-496	-9.00	-555	21.00	815	-10.00	26,406
Cashflow From Financing	-100.0%	-	97.00	21,205	69,338	-2,124	60,644	51,977	-347	4,956	24,570	-4,442	-924	55,041	7,629	-284	65.00	4,984	60,284	-6,414	86,678	113
Buy Backs	-	-	-	-	-	443	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XFOR Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 19,854	$ 22,063
Selling, general and administrative	17,435	7,241
Total operating expenses	37,289	29,304
Loss from operations	(37,289)	(29,304)
Other (expense) income, net:
Interest income	1,066	835
Interest expense	(1,874)	(1,109)
Other income, net	105	123
Total other (expense) income, net	(14,458)	5,288
Loss before provision for income taxes	(51,747)	(24,016)
Provision for income taxes	19	4
Net loss	$ (51,766)	$ (24,020)
Net loss per share attributable to common stockholders—basic	$ (0.26)	$ (0.16)
Net loss per share attributable to common stockholders—diluted	$ (0.26)	$ (0.16)
Weighted average shares of common stock outstanding—diluted	199,991,597	145,967,476
Weighted average shares of common stock outstanding—basic	199,991,597	145,967,476
Supplemental Income Statement Elements [Abstract]
Change in unrealized loss related to available-for-sale debt securities	$ (36)	$ 0
Comprehensive loss	(51,802)	(24,020)
Warrant Liability
Other (expense) income, net:
Derivative, gain (loss) on derivative, net	$ (13,755)	$ 5,439

XFOR Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 60,493	$ 99,216
Marketable securities	20,376	15,000
Research and development incentive receivable	702	562
Prepaid expenses and other current assets	5,762	7,298
Total current assets	87,333	122,076
Property and equipment, net	742	745
Goodwill	17,351	17,351
Right-of-use assets	5,264	5,650
Other assets	1,492	1,436
Total assets	112,182	147,258
Current liabilities:
Accounts payable	8,935	8,947
Accrued expenses	13,473	12,816
Current portion of lease liability	1,133	1,099
Total current liabilities	23,541	22,862
Long-term debt, including accretion, net of discount	54,824	54,570
Lease liabilities	2,318	2,612
Warrant liability (Note 4)	29,438	15,683
Other liabilities	1,025	432
Total liabilities	111,146	96,159
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.001 par value, 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 167,937,781 and 167,434,595 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	168	167
Additional paid-in capital	530,694	528,956
Accumulated other comprehensive loss	(155)	(119)
Accumulated deficit	(529,671)	(477,905)
Total stockholders’ equity	1,036	51,099
Total liabilities and stockholders’ equity	$ 112,182	$ 147,258

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and WaldenstrÃƒÂ¶m macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

CEO	Dr. Paula Ragan Ph.D.
WEBSITE	x4pharma.com
INDUSTRY	Biotechnology
EMPLOYEES	40

X4 Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for X4 Pharmaceuticals Inc? What does XFOR stand for in stocks?

XFOR is the stock ticker symbol of X4 Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of X4 Pharmaceuticals Inc (XFOR)?

As of Fri May 17 2024, market cap of X4 Pharmaceuticals Inc is 156.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XFOR stock?

You can check XFOR's fair value in chart for subscribers.

What is the fair value of XFOR stock?

You can check XFOR's fair value in chart for subscribers. The fair value of X4 Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of X4 Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XFOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is X4 Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XFOR is over valued or under valued. Whether X4 Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact X4 Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XFOR.

What is X4 Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, XFOR's PE ratio (Price to Earnings) is -1.21 and Price to Sales (PS) ratio is 61.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XFOR PE ratio will change depending on the future growth rate expectations of investors.